Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PV-MF”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Study completedNCT02515630
What this trial is testing

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis
Sierra Oncology LLC - a GSK company 41
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Testing effectiveness (Phase 2)Study completedNCT00946270
What this trial is testing

Pomalidomide for Myelofibrosis Patients

Who this might be right for
Polycythemia VeraThrombocythemia
M.D. Anderson Cancer Center 70
Large-scale testing (Phase 3)Looking for participantsNCT06479135
What this trial is testing

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+2 more
Kartos Therapeutics, Inc. 600
Large-scale testing (Phase 3)Study completedNCT02101268
What this trial is testing

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sierra Oncology LLC - a GSK company 156
Testing effectiveness (Phase 2)Study completedNCT02098161
What this trial is testing

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisSecondary Myelofibrosis
M.D. Anderson Cancer Center 50
Large-scale testing (Phase 3)Active Not RecruitingNCT04717414
What this trial is testing

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Who this might be right for
Myeloproliferative DisordersMyelofibrosisPrimary Myelofibrosis+2 more
Celgene 313
Not applicableNo Longer AvailableNCT05582083
What this trial is testing

Managed Access Program for Momelotinib in Myelofibrosis

Who this might be right for
MyelofibrosisPrimary Myelofibrosis
GlaxoSmithKline
Early research (Phase 1)Not Yet RecruitingNCT07340138
What this trial is testing

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)UnknownNCT04878003
What this trial is testing

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Kartos Therapeutics, Inc. 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT04446650
What this trial is testing

Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Who this might be right for
Primary Myelofibrosis
Bristol-Myers Squibb 31
Early research (Phase 1)Ended earlyNCT03935555
What this trial is testing

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Samus Therapeutics, Inc. 11
Testing effectiveness (Phase 2)Ended earlyNCT02730884
What this trial is testing

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Who this might be right for
LeukemiaMyelofibrosisAnemia+1 more
M.D. Anderson Cancer Center 3
Not applicableActive Not RecruitingNCT06798805
What this trial is testing

Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms

Who this might be right for
Essential Thrombocythemia (ET)Myelofibrosis (MF)Polycythemia Vera (PV)
IRCCS Azienda Ospedaliero-Universitaria di Bologna 110
Large-scale testing (Phase 3)Ended earlyNCT03755518
What this trial is testing

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more
Celgene 38
Testing effectiveness (Phase 2)UnknownNCT04485260
What this trial is testing

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
Myelofibrosis
Kartos Therapeutics, Inc. 36
Early research (Phase 1)UnknownNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Early research (Phase 1)Looking for participantsNCT07469891
What this trial is testing

PRT12396 in Participants With Select Myeloproliferative Neoplasms

Who this might be right for
Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)+3 more
Prelude Therapeutics 100
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Not applicableStudy completedNCT00715247
What this trial is testing

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Who this might be right for
Polycythemia VeraEssential ThrombocythemiaMyelofibrosis
University of Utah 726
Load More Results